Flotillin-1 expression in human clear-cell renal cell carcinoma is associated with cancer progression and poor patient survival

Zhang,Yiyan; Li,Jijun; Song,Yan; Chen,Fengkun; Pei,Yin; Yao,Fenghua

doi:10.3892/mmr.2014.2310

Flotillin-1 expression in human clear-cell renal cell carcinoma is associated with cancer progression and poor patient survival

Authors:
- Yiyan Zhang
- Jijun Li
- Yan Song
- Fengkun Chen
- Yin Pei
- Fenghua Yao
View Affiliations

Affiliations: Department of Nephrology, First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, P.R. China
Published online on: June 10, 2014 https://doi.org/10.3892/mmr.2014.2310
Pages: 860-866

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was designed to elucidate the expression levels and the proliferative effect of flotillin-1, an integral membrane protein encoded by the FLOT1 gene, in human clear-cell renal cell carcinoma (RCC). Flotillin has been implicated in other types of cancer, but the role of flotillin in RCC has not been established. Immunohistochemistry and western blotting were used to determine FLOT1 protein expression levels in RCC samples from 182 patients who underwent nephrectomy. FLOT1 mRNA expression levels were analyzed using reverse-transcription (RT) and RT-quantitative polymerase chain reaction (PCR). The association between FLOT1 expression levels in the tumor samples and patient survival time was examined using Kaplan‑Meier analysis. To demonstrate the proliferative effect of FLOT1 on RCC cells, a FLOT1 vector was transfected into four RCC cell lines and FLOT1 expression was inhibited using small interfering RNA. The proliferative ability of the RCC cells was investigated using a WST-1 assay and xenograft experiments with BALB/C nude mice. The results demonstrated that FLOT1 expression levels were significantly higher in RCC cell samples from patients than in healthy renal tissue, and the expression levels were associated with tumor stage, size and histological grade. In addition, FLOT1 significantly enhanced the proliferation of RCC cell lines in vitro and in vivo. These findings suggest that FLOT1, which is upregulated in RCC, is involved in RCC cell proliferation, tumorigenesis and progression. Therefore, FLOT1 is an independent prognostic marker and therapeutic target for patients with clear-cell RCC.

View Figures

View References

1	Deng FM and Melamed J: Histologic variants of renal cell carcinoma: does tumor type influence outcome? Urol Clin North Am. 39:119–132. 2012. View Article : Google Scholar : PubMed/NCBI
2	Athar U and Gentile TC: Treatment options for metastatic renal cell carcinoma: a review. Can J Urol. 15:3954–3966. 2008.PubMed/NCBI
3	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar
4	Yu DS, Chang SY and Ma CP: The expression of MDR-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines. Br J Urol. 82:544–547. 1998. View Article : Google Scholar : PubMed/NCBI
5	Hartmann JT and Bokemeyer C: Chemotherapy for renal cell carcinoma. Anticancer Res. 19:1541–1543. 1999.PubMed/NCBI
6	Coppin C: Immunotherapy for renal cell cancer in the era of targeted therapy. Expert Rev Anticancer Ther. 8:907–919. 2008. View Article : Google Scholar : PubMed/NCBI
7	Dalle S, Thieblemont C, Thomas L and Dumontet C: Monoclonal antibodies in clinical oncology. Anticancer Agents Med Chem. 8:523–532. 2008. View Article : Google Scholar
8	Sciarra A, Gentile V, Salciccia S, Alfarone A and Di Silverio F: New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects. Rev Recent Clin Trials. 3:97–103. 2008. View Article : Google Scholar : PubMed/NCBI
9	Simpson D and Curran MP: Temsirolimus: in advanced renal cell carcinoma. Drugs. 68:631–638. 2008. View Article : Google Scholar : PubMed/NCBI
10	Lam JS, Pantuck AJ, Belldegrun AS and Figlin RA: Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials. Clin Cancer Res. 13:703s–708s. 2007. View Article : Google Scholar : PubMed/NCBI
11	Netto GJ and Cheng L: Emerging critical role of molecular testing in diagnostic genitourinary pathology. Arch Pathol Lab Med. 136:372–390. 2012. View Article : Google Scholar : PubMed/NCBI
12	Lingwood D and Simons K: Lipid rafts as a membrane-organizing principle. Science. 327:46–50. 2010. View Article : Google Scholar : PubMed/NCBI
13	Jacobson K, Mouritsen OG and Anderson RG: Lipid rafts: at a crossroad between cell biology and physics. Nat Cell Biol. 9:7–14. 2007. View Article : Google Scholar : PubMed/NCBI
14	Simons K and Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 1:31–39. 2000. View Article : Google Scholar
15	Patra SK: Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta. 1785:182–206. 2008.PubMed/NCBI
16	Patra SK and Bettuzzi S: Epigenetic DNA-methylation regulation of genes coding for lipid raft-associated components: a role for raft proteins in cell transformation and cancer progression (review). Oncol Rep. 17:1279–1290. 2007.PubMed/NCBI
17	Mollinedo F, de la Iglesia-Vicente J, Gajate C, et al: Lipid raft-targeted therapy in multiple myeloma. Oncogene. 29:3748–3757. 2010. View Article : Google Scholar : PubMed/NCBI
18	Hitosugi T, Sato M, Sasaki K and Umezawa Y: Lipid raft specific knockdown of SRC family kinase activity inhibits cell adhesion and cell cycle progression of breast cancer cells. Cancer Res. 67:8139–8148. 2007. View Article : Google Scholar : PubMed/NCBI
19	Lang DM, Lommel S, Jung M, et al: Identification of reggie-1 and reggie-2 as plasmamembrane-associated proteins which cocluster with activated GPI-anchored cell adhesion molecules in non-caveolar micropatches in neurons. J Neurobiol. 37:502–523. 1998. View Article : Google Scholar
20	Stuermer CA, Lang DM, Kirsch F, et al: Glycosylphosphatidyl inositol-anchored proteins and fyn kinase assemble in noncaveolar plasma membrane microdomains defined by reggie-1 and -2. Mol Biol Cell. 12:3031–3045. 2001. View Article : Google Scholar
21	Schulte T, Paschke KA, Laessing U, Lottspeich F and Stuermer CA: Reggie-1 and reggie-2, two cell surface proteins expressed by retinal ganglion cells during axon regeneration. Development. 124:577–587. 1997.PubMed/NCBI
22	Banning A, Tomasovic A and Tikkanen R: Functional aspects of membrane association of reggie/flotillin proteins. Curr Protein Pept Sci. 12:725–735. 2011. View Article : Google Scholar : PubMed/NCBI
23	Baumann CA, Ribon V, Kanzaki M, et al: CAP defines a second signaling pathway required for insulin-stimulated glucose transport. Nature. 407:202–207. 2000. View Article : Google Scholar : PubMed/NCBI
24	Riento K, Frick M, Schafer I and Nichols BJ: Endocytosis of flotillin-1 and flotillin-2 is regulated by Fyn kinase. J Cell Sci. 122:912–918. 2009. View Article : Google Scholar : PubMed/NCBI
25	Song L, Gong H, Lin C, et al: Flotillin-1 promotes tumor necrosis factor-alpha receptor signaling and activation of NF-kappaB in esophageal squamous cell carcinoma cells. Gastroenterology. 143:995–1005. 2012. View Article : Google Scholar : PubMed/NCBI
26	Hazarika P, McCarty MF, Prieto VG, et al: Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res. 64:7361–7369. 2004. View Article : Google Scholar : PubMed/NCBI
27	Santamaría A, Castellanos E, Gómez V, et al: PTOV1 enables the nuclear translocation and mitogenic activity of flotillin-1, a major protein of lipid rafts. Mol Cell Biol. 25:1900–1911. 2005.PubMed/NCBI
28	Thorn CC, Freeman TC, Scott N, Guillou PJ and Jayne DG: Laser microdissection expression profiling of marginal edges of colorectal tumours reveals evidence of increased lactate metabolism in the aggressive phenotype. Gut. 58:404–412. 2009. View Article : Google Scholar
29	Lin C, Wu Z, Lin X, et al: Knockdown of FLOT1 impairs cell proliferation and tumorigenicity in breast cancer through upregulation of FOXO3a. Clin Cancer Res. 17:3089–3099. 2011. View Article : Google Scholar : PubMed/NCBI
30	Gómez V, Sesé M, Santamaría A, et al: Regulation of aurora B kinase by the lipid raft protein flotillin-1. J Biol Chem. 285:20683–20690. 2010.PubMed/NCBI
31	Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
32	Delahunt B, Sika-Paotonu D, Bethwaite PB, William Jordan T, Magi-Galluzzi C, Zhou M, Samaratunga H and Srigley JR: Grading of clear cell renal cell carcinoma should be based on nucleolar prominence. Am J Surg Pathol. 35:1134–1139. 2011. View Article : Google Scholar : PubMed/NCBI
33	Zhang SH, Wang CJ, Shi L, et al: High expression of FLOT1 is associated with progression and poor prognosis in hepatocellular carcinoma. PLoS ONE. 8:e647092013. View Article : Google Scholar : PubMed/NCBI
34	Pust S, Klokk TI, Musa N, et al: Flotillins as regulators of ErbB2 levels in breast cancer. Oncogene. 32:3443–3451. 2013. View Article : Google Scholar : PubMed/NCBI
35	Lin C, Wu Z, Lin X, et al: Knockdown of FLOT1 impairs cell proliferation and tumorigenicity in breast cancer through upregulation of FOXO3a. Clin Cancer Res. 17:3089–3099. 2011. View Article : Google Scholar : PubMed/NCBI